| Nov 19 |
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright
|
| Oct 9 |
Individual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46%
|
| Sep 24 |
Milestone Pharmaceuticals to Host Investor KOL Event
|
| Sep 6 |
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
|
| Sep 4 |
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
|
| Sep 3 |
Milestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 26 |
Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024
|
| Aug 22 |
Milestone wins Buy at Rodman & Renshaw on potential Cardamyst approval
|
| Aug 9 |
Milestone Pharmaceuticals GAAP EPS of -$0.14
|
| Jul 31 |
Milestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference
|
